A herb-based hair dye formulation includes one or more ingredients selected from coloring agent, enhancing agent, toning agent and auxiliary agent of herb origin. Also disclosed is a method for producing a herb-based product, and particularly a method for manufacturing the herb-based hair dye formulation.

A herb-based hair dye formulation includes one or more ingredients selected from coloring agent, enhancing agent, toning agent and auxiliary agent of herb origin. Also disclosed is a method for producing a herb-based product, and particularly a method for manufacturing the herb-based hair dye formulation.

A pharmaceutical or cosmetic composition is provided. The composition includes an Indigo Naturalis or Indigo-producing plant extract, for inhibiting Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus. A method of inhibiting Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, is also provided. The method includes contacting a cell with an effective amount of an Indigo Naturalis or Indigo-producing plant extract.

A pharmaceutical or cosmetic composition is provided. The composition includes an Indigo Naturalis or Indigo-producing plant extract, for inhibiting Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus. A method of inhibiting Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, is also provided. The method includes contacting a cell with an effective amount of an Indigo Naturalis or Indigo-producing plant extract.

A medicament for use in treating gout, the medicament being a glycoprotein, a mixture of polysaccharide and protein, a polypeptide or a protein.

A medicament for use in treating gout, the medicament being a glycoprotein, a mixture of polysaccharide and protein, a polypeptide or a protein.

A medicament for use in treating gout, the medicament being a glycoprotein, a mixture of polysaccharide and protein, a polypeptide or a protein.

A refined Indigo Naturalis extract or Indigo-producing plant extract containing at least 65% (w/w) an indirubin derivative based on total weight of active ingredients is described. Also described are a pharmaceutical composition containing the refined extract, and the use of the pharmaceutical composition for treating or alleviating a disease or condition.

A refined Indigo Naturalis extract or Indigo-producing plant extract containing at least 65% (w/w) an indirubin derivative based on total weight of active ingredients is described. Also described are a pharmaceutical composition containing the refined extract, and the use of the pharmaceutical composition for treating or alleviating a disease or condition.

Kits for the treatment or prophylaxis of depressed mood are described, for subjects with increased MAO-A levels, excessive crying, or subjects within or beyond the 5-day postpartum period. The kits are used to implement a method by which the subject is administered an antioxidant source on at least the first day of a 3 to 5 day regime; a tryptophan composition on the evening of the penultimate treatment day, simultaneously or following the antioxidant source; and a tyrosine composition the day after the tryptophan composition, on the final treatment day. The kit comprises an antioxidant source which may comprise or be derived from blueberries. Individuals with depressed mood due to perimenopause, alcohol use disorders or withdrawal, or who are up to or beyond 18-months postpartum, may benefit from the kits. The kits described may reduce the likelihood of advancing from depressed mood to depression.